Advertisement

Medical Oncology

, 31:155 | Cite as

Involvement of chromosome region maintenance 1 (CRM1) in the formation and progression of esophageal squamous cell carcinoma

  • Xiaojing Yang
  • Lei Cheng
  • Li Yao
  • Hanru Ren
  • Shu Zhang
  • Xiao Min
  • Xueyu Chen
  • Jianguo Zhang
  • Mei Li
Original Paper

Abstract

Chromosome region maintenance 1 (CRM1) has been related to several malignancies. The predictive value of CRM1 in the malignance and prognosis of esophageal squamous cell carcinoma (ESCC), however, is not clear yet. In this study, we displayed that CRM1 expression was up-regulated in ESCC using immunohistochemistry and Western blot. Statistical analysis demonstrated that patients with high CRM1 levels indicated shorter survival period. We further found that silencing CRM1 caused apoptosis in ESCC cell lines. Moreover, knockdown of CRM1 disturbed the expression of tumor suppressor proteins and inhibited NF-κB activity in ESCC cell lines, especially if the cell line was treated with 5-fluorouracil. In consequence, our results for the first time indicated that CRM1 was dysregulated in ESCC, and suppression of CRM1 expression which resulted in inhibiting of NF-κB signaling might be developed into a new strategy in ESCC therapy.

Keywords

Esophageal squamous cell carcinoma (ESCC) Chromosome region maintenance 1 (CRM1) Apoptosis Prognosis Chemotherapy 

Notes

Acknowledgments

The authors acknowledge the Development Fund for Collaborative Innovation Center of Glycoscience of Shandong University, a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

Conflict of interest

The authors disclose no conflicts.

References

  1. 1.
    Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241–52.PubMedCrossRefGoogle Scholar
  3. 3.
    van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.PubMedCrossRefGoogle Scholar
  4. 4.
    Lin J, Beerm DG. Molecular biology of upper gastrointestinal malignancies. Semin Oncol. 2004;31(4):476–86.PubMedCrossRefGoogle Scholar
  5. 5.
    Wang XX, Liu R, Jin SQ, Fan FY, Zhan QM. Overexpression of Aurora-A kinase promotes tumor cell proliferation and inhibits apoptosis in esophageal squamous cell carcinoma cell line. Cell Res. 2006;16(4):356–66.PubMedCrossRefGoogle Scholar
  6. 6.
    Sjostrom J, Bergh J. How apoptosis is regulated, and what goes wrong in cancer. BMJ. 2001;322(7301):1538–9.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol. 2007;17(4):193–201.PubMedCrossRefGoogle Scholar
  8. 8.
    Fornerod M, Ohno M, Yoshida M, Mattaj IW. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell. 1997;90(6):1051–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Huang TT, Kudo N, Yoshida M, Miyamoto S. A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc Natl Acad Sci USA. 2000;97(3):1014–9.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, Sun YJ. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med. 2009;32(6):E315.PubMedGoogle Scholar
  11. 11.
    Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen P, et al. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep. 2009;21(1):229–35.PubMedGoogle Scholar
  12. 12.
    Noske A, Weichert W, Niesporek S, Roske A, Buckendahl AC, Koch I, et al. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer. 2008;112(8):1733–43.PubMedCrossRefGoogle Scholar
  13. 13.
    Shao C, Lu C, Chen L, Koty PP, Cobos E, Gao W. p53-Dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemother Pharmacol. 2011;67(6):1369–80.PubMedCrossRefGoogle Scholar
  14. 14.
    van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, et al. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer. 2009;124(8):1829–40.PubMedCrossRefGoogle Scholar
  15. 15.
    Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ, et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood. 2012;119(2):329–31.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013;121(20):4166–74.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Zhang J, Yang X, Wang Y, Shi H, Guan C, Yao L et al. Low expression of CYCLINH and cyclin-dependent kinase 7 can decrease the proliferation of human esophageal squamous cell carcinoma. Dig Dis Sci. 2013;58(7):2028–37.PubMedCrossRefGoogle Scholar
  18. 18.
    Wang Y, Zhou S, Yang X, Shi H, Li M, Xue Q, et al. Low expression of cyclic AMP response element modulator-1 can increase the migration and invasion of esophageal squamous cell carcinoma. Tumour Biol. 2013;34(6):3649–57.PubMedCrossRefGoogle Scholar
  19. 19.
    Wang Y, Liu DP, Chen PP, Koeffler HP, Tong XJ, Xie D. Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers. Cancer Res. 2007;67(6):2535–43.PubMedCrossRefGoogle Scholar
  20. 20.
    Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2013.Google Scholar
  21. 21.
    Favaloro B, Allocati N, Graziano V, Di Ilio C, De Laurenzi V. Role of apoptosis in disease. Aging (Albany, NY). 2012;4(5):330–49.Google Scholar
  22. 22.
    Chen L, Moore JE, Samathanam C, Shao C, Cobos E, Miller MS, et al. CRM1-dependent p53 nuclear accumulation in lung lesions of a bitransgenic mouse lung tumor model. Oncol Rep. 2011;26(1):223–8.PubMedGoogle Scholar
  23. 23.
    Tam WF, Lee LH, Davis L, Sen R. Cytoplasmic sequestration of rel proteins by IkappaBalpha requires CRM1-dependent nuclear export. Mol Cell Biol. 2000;20(6):2269–84.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Tian F, Fan T, Jiang Y, Zhang X, Wang X. A small interfering RNA targeting NF-kappaB p65 alone or combined with 5-FU inhibits growth of esophageal squamous cell carcinoma in nude mice. Pathol Res Pract. 2012;208(1):32–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Wang W, Xue L, Wang P. Prognostic value of beta-catenin, c-myc, and cyclin D1 expressions in patients with esophageal squamous cell carcinoma. Med Oncol. 2011;28(1):163–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Tian F, Zang WD, Hou WH, Liu HT, Xue LX. Nuclear factor-kB signaling pathway constitutively activated in esophageal squamous cell carcinoma cell lines and inhibition of growth of cells by small interfering RNA. Acta Biochim Biophys Sin (Shanghai). 2006;38(5):318–26.CrossRefGoogle Scholar
  27. 27.
    Ramaswami S, Manna S, Juvekar A, Kennedy S, Vancura A, Vancurova I. Chromatin immunoprecipitation analysis of NFkappaB transcriptional regulation by nuclear IkappaBalpha in human macrophages. Methods Mol Biol. 2012;809:121–34.PubMedCrossRefGoogle Scholar
  28. 28.
    Chuang-Xin L, Wen-Yu W, Yao C, Xiao-Yan L, Yun Z. Quercetin enhances the effects of 5-fluorouracil-mediated growth inhibition and apoptosis of esophageal cancer cells by inhibiting NF-kappaB. Oncol Lett. 2012;4(4):775–8.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery. 2009;65(1):153–9 (discussion 9–60).PubMedCrossRefGoogle Scholar
  30. 30.
    Mandard AM, Hainaut P, Hollstein M. Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res. 2000;462(2–3):335–42.PubMedCrossRefGoogle Scholar
  31. 31.
    Hsia JY, Chen CY, Hsu CP, Shai SE, Yang SS, Chuang CY, et al. Expression of apoptosis-regulating proteins p53, Bcl-2, and Bax in primary resected esophageal squamous cell carcinoma. Neoplasma. 2001;48(6):483–8.PubMedGoogle Scholar
  32. 32.
    Taghavi N, Biramijamal F, Sotoudeh M, Moaven O, Khademi H, Abbaszadegan MR, et al. Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients. World J Gastroenterol. 2010;16(39):4958–67.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Li B, Cheung PY, Wang X, Tsao SW, Ling MT, Wong YC, et al. Id-1 activation of PI3K/Akt/NFkappaB signaling pathway and its significance in promoting survival of esophageal cancer cells. Carcinogenesis. 2007;28(11):2313–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Golomb L, Bublik DR, Wilder S, Nevo R, Kiss V, Grabusic K, et al. Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol Cell. 2012;45(2):222–32.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    van der Watt PJ, Leaner VD. The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage. Biochim Biophys Acta. 2011;1809(7):316–26.PubMedCrossRefGoogle Scholar
  36. 36.
    Leskov KS, Araki S, Lavik JP, Gomez JA, Gama V, Gonos ES, et al. CRM1 protein-mediated regulation of nuclear clusterin (nCLU), an ionizing radiation-stimulated. Bax-dependent pro-death factor. J Biol Chem. 2011;286(46):40083–90.Google Scholar
  37. 37.
    Tian F, Fan T, Zhang Y, Jiang Y, Zhang X. Curcumin potentiates the antitumor effects of 5-FU in treatment of esophageal squamous carcinoma cells through downregulating the activation of NF-kappaB signaling pathway in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai). 2012;44(10):847–55.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Xiaojing Yang
    • 2
    • 3
  • Lei Cheng
    • 4
  • Li Yao
    • 2
  • Hanru Ren
    • 1
  • Shu Zhang
    • 1
  • Xiao Min
    • 5
  • Xueyu Chen
    • 6
  • Jianguo Zhang
    • 1
  • Mei Li
    • 7
  1. 1.Department of PathologyAffiliated Hospital of Nantong UniversityNantongPeople’s Republic of China
  2. 2.Jiangsu Province Key Laboratory for Inflammation and Molecular Drug TargetNantong UniversityJiangsuPeople’s Republic of China
  3. 3.Department of OncologyShanghai Jiao Tong University Affiliated Sixth People’s HospitalShanghaiChina
  4. 4.Department of Laparoscopic Surgerythe First Affiliated Hospital of Dalian Medical UniversityDalianPeople’s Republic of China
  5. 5.National Glycoengineering Research Center, State Key Laboratory of Microbial TechnologyShandong UniversityJinanPeople’s Republic of China
  6. 6.Shanghai Institute of Materia MedicaChinese Academy of SciencesShanghaiPeople’s Republic of China
  7. 7.Department of OncologyAffiliated Hospital of Nantong UniversityNantongPeople’s Republic of China

Personalised recommendations